Loading clinical trials...
Loading clinical trials...
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Conditions
Interventions
NEOD001
Locations
5
United States
Stanford Cancer Institute (SCI)
Stanford, California, United States
Tufts Medical Center
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
February 1, 2016
Primary Completion Date
May 1, 2018
Completion Date
May 1, 2018
Last Updated
May 16, 2019
NCT06383143
NCT06192979
NCT07250269
NCT06022939
NCT04839003
NCT05066607
Lead Sponsor
Prothena Biosciences Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions